Business
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE \nAvidity joins with MDF community leaders, patients, caregivers, and legislators in educational briefing to highlight the latest scientific advancements in myotonic dystrophy research and development\nCompany advancing clinical development programs for three types of muscular dystrophy – DM1, DMD and FSHD – with planned data readouts over the next 12 months\nSAN DIEGO, Sept. 7, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases. Today, Avidity will be joining Myotonic Dystrophy Foundation (MDF) community leaders, patients, caregivers, and legislators to raise awareness of myotonic dystrophy and the importance of advancing research to develop new treatments for the disease as part of a special MDF Advocacy Day on Capitol Hill in Washington, D.C. In addition, Avidity is engaging with patient communities to support World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD, and Global Genes Week in RARE, all taking place during National Muscular Dystrophy Awareness Month.\n\n \n \n \n \n \n \n\n \n\"We are proud to be uniting with patient communities and their families this month to raise awareness of muscular dystrophy. Today, we are joining MDF as part of an educational briefing on Capitol Hill and also, recognizing World Duchenne Awareness Day. Later this month, we will be engaging with members of the FSHD community and Global Genes,\" said Sarah Boyce, president and chief executive officer at Avidity. \"At Avidity, we are developing a new class of treatments and advancing three distinct clinical development programs for three types of muscular dystrophy – DM1, DMD and FSHD. Many people living with these devastating muscle disorders have limited or no treatment options. It is important that we work together a...